Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Carcinoma
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Cross-Sectional
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed vi...
PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.
Tracking Information
- NCT #
- NCT02610413
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Bryan P Schneider Eastern Cooperative Oncology Group
Get Well Soon